Un-Audited Financial Results (UFR) for the Third quarter and Nine Months ended December 31, 2025, along with the Statutory Auditors' Limited Review Report.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natural Biocon (India) Ltd reported zero revenue from operations for the October-December 2025 quarter, down from Rs. 127.73 lakhs in the same quarter last year. For the nine-month period (April-December 2025), revenue stood at Rs. 166.57 lakhs, a sharp drop of about 72% from Rs. 601.42 lakhs in the corresponding period of FY25. The company posted a loss after tax of Rs. 4.27 lakhs in Q3, compared to a profit of Rs. 24.59 lakhs a year ago. Nine-month profit after tax came in at Rs. 5.23 lakhs, down from Rs. 44.83 lakhs previously. Basic EPS turned negative at Rs. (0.02) for the quarter. The statutory auditor issued a clean limited review report with no qualifications or emphasis of matter.
The complete halt in quarterly sales is a serious red flag for shareholders, suggesting either a business disruption or a winding down of operations. With no revenue being generated but fixed employee and overhead expenses still being incurred, the company is burning cash, which could pressure the stock price and raise questions about future viability.